Professional Summary
Professional Overview
Jeffrey Bartlett is a seasoned biotechnology executive with over 20 years of experience in gene therapy research, development, and strategic leadership. As the CTO/CIO and Co-Founder of Rampart Bioscience, he leverages his deep expertise in molecular virology, immunology, and gene therapy to drive innovation and accelerate the company's pipeline of transformative therapies.
Experience Summary
Current Role
As the CTO/CIO and Co-Founder of Rampart Bioscience, Jeffrey is responsible for overseeing the company's technical strategy, research and development efforts, and information technology infrastructure. He plays a pivotal role in shaping the company's long-term vision, driving scientific breakthroughs, and ensuring the seamless integration of cutting-edge technologies to support Rampart's mission.
Career Progression
Prior to founding Rampart Bioscience, Jeffrey held several senior leadership positions in the biotechnology industry. He served as the Senior Director of Gene Therapy Strategic Development at CSL Behring, where he spearheaded the company's strategic initiatives in gene therapy. Before that, he held the roles of Chief Scientific Officer and Senior Vice President of Research and Development at Calimmune, Inc., where he led the development of novel gene therapy approaches for rare genetic disorders.
Earlier in his career, Jeffrey was an Associate Professor of Pediatrics and Molecular Virology, Immunology, and Medical Genetics at The Ohio State University. He also served as an Investigator at the Center for Gene Therapy and the Center for Childhood Cancer at The Research Institute at Nationwide Children's Hospital.
Academic Background
Jeffrey holds a Ph.D. in Molecular Virology and Immunology from the University of North Carolina at Chapel Hill. He has a strong academic background, with a focus on pulmonary and cystic fibrosis research, and has published extensively in peer-reviewed journals.
Areas of Expertise
- Gene therapy research and development
- Molecular virology and immunology
- Rare genetic disorder therapeutics
- Technical strategy and innovation
- Biotechnology industry leadership
- Research program management
- Translational research and clinical development
Professional Impact
Throughout his career, Jeffrey has made significant contributions to the field of gene therapy, including the development of novel viral vector platforms and the advancement of cutting-edge therapies for rare genetic disorders. His work has had a tangible impact on improving patient outcomes and advancing the field of biotechnology.
Conclusion
With his extensive experience, deep scientific expertise, and proven track record of successful biotechnology leadership, Jeffrey Bartlett is poised to lead Rampart Bioscience in its mission to develop transformative gene therapy solutions that address unmet medical needs.
